Skip to main content
Erschienen in: World Journal of Urology 2/2017

03.06.2016 | Original Article

Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins

verfasst von: Christian P. Meyer, Jens Hansen, Katharina Boehm, Derya Tilki, Firas Abdollah, Quoc-Dien Trinh, Margit Fisch, Guido Sauter, Markus Graefen, Hartwig Huland, Felix K. H. Chun, Sascha A. Ahyai

Erschienen in: World Journal of Urology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop a novel application evaluating the effect of tumor volume (TV) and percentage of high-grade tumor volume (%HGTV) on long-term biochemical recurrence-free survival rate (BCRFS) after radical prostatectomy (RP) in patients with pT2 PCa.

Methods

Retrospective analysis of 903 men with pT2 PCa between 1992 and 2004 at a single European tertiary care center was performed. Cox regression models identified risk factors for BCR. A nomogram was developed to predict the BCRFS at 5, 10 and 15 years after RP. Decision curve analyses were performed to identify the net increase in cases identified by the full model.

Results

BCR-free survival rates at 5, 10 and 15 years were 94, 90 and 86 %. In Cox regression analyses, TV, %HGTV and positive surgical margin status (SM) were independent predictors of BCR. Predictive accuracies (PA) at 5, 10 and 15 years of the base model (PSA, Gleason score, SM) were 76.8 % (95 % CI 67.9–78.2 %), 70.5 % (95 % CI 64.9–75.0 %) and 68.1 % (95 % CI 60.6–73.5 %). The full model, including TV and %HGTV, achieved 76.9, 72.4 and 70.7 %. These PA differences were statistically significant at 10 and 15 years (p < 0.001).

Conclusions

TV and %HGTV could potentially serve as valuable measures to stratify patients at high risk of BCR. The use of our nomogram should be considered to counsel patients with pT2 disease and SM and to design appropriate follow-up or treatment regimens.
Literatur
3.
Zurück zum Zitat Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA Jr, Barocas DA (2009) Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol 182(6):2695–2701. doi:10.1016/j.juro.2009.08.054 CrossRefPubMed Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA Jr, Barocas DA (2009) Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol 182(6):2695–2701. doi:10.​1016/​j.​juro.​2009.​08.​054 CrossRefPubMed
4.
7.
Zurück zum Zitat Ahyai SA, Zacharias M, Isbarn H, Steuber T, Eichelberg C, Kollermann J, Fisch M, Karakiewicz PI, Huland H, Graefen M, Chun FK (2010) Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. BJU Int 106(4):478–483. doi:10.1111/j.1464-410X.2009.09162.x CrossRefPubMed Ahyai SA, Zacharias M, Isbarn H, Steuber T, Eichelberg C, Kollermann J, Fisch M, Karakiewicz PI, Huland H, Graefen M, Chun FK (2010) Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. BJU Int 106(4):478–483. doi:10.​1111/​j.​1464-410X.​2009.​09162.​x CrossRefPubMed
8.
Zurück zum Zitat Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ (2004) Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172(1):137–140. doi:10.1097/01.ju.0000132139.40964.75 CrossRefPubMed Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ (2004) Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172(1):137–140. doi:10.​1097/​01.​ju.​0000132139.​40964.​75 CrossRefPubMed
9.
Zurück zum Zitat Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H (2002) Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 41(2):155–161CrossRefPubMed Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H (2002) Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 41(2):155–161CrossRefPubMed
10.
Zurück zum Zitat Merrill MM, Lane BR, Reuther AM, Zhou M, Magi-Galluzzi C, Klein EA (2007) Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 70(2):294–298. doi:10.1016/j.urology.2007.03.062 CrossRefPubMed Merrill MM, Lane BR, Reuther AM, Zhou M, Magi-Galluzzi C, Klein EA (2007) Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 70(2):294–298. doi:10.​1016/​j.​urology.​2007.​03.​062 CrossRefPubMed
11.
Zurück zum Zitat Song C, Kang T, Yoo S, Jeong IG, Ro JY, Hong JH, Kim CS, Ahn H (2011) Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urol Oncol. doi:10.1016/j.urolonc.2010.11.005 Song C, Kang T, Yoo S, Jeong IG, Ro JY, Hong JH, Kim CS, Ahn H (2011) Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urol Oncol. doi:10.​1016/​j.​urolonc.​2010.​11.​005
12.
Zurück zum Zitat Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Walz J, Eichelberg C, Salomon G, Haese A, Currlin E, Ahyai SA, Benard F, Huland H, Graefen M, Karakiewicz PI (2007) Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 43(3):536–543. doi:10.1016/j.ejca.2006.10.018 CrossRefPubMed Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Walz J, Eichelberg C, Salomon G, Haese A, Currlin E, Ahyai SA, Benard F, Huland H, Graefen M, Karakiewicz PI (2007) Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 43(3):536–543. doi:10.​1016/​j.​ejca.​2006.​10.​018 CrossRefPubMed
14.
Zurück zum Zitat Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F, Vordos D, Cicco A, Hoznek A, Chopin D, Abbou CC (2003) Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43(1):39–44CrossRefPubMed Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F, Vordos D, Cicco A, Hoznek A, Chopin D, Abbou CC (2003) Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43(1):39–44CrossRefPubMed
15.
Zurück zum Zitat Greene FPD, Fleming I et al (2002) American Joint Committee on cancer staging manual, 6th edn. Springer, New YorkCrossRef Greene FPD, Fleming I et al (2002) American Joint Committee on cancer staging manual, 6th edn. Springer, New YorkCrossRef
16.
Zurück zum Zitat Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H (2001) A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 165(3):857–863CrossRefPubMed Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H (2001) A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 165(3):857–863CrossRefPubMed
17.
Zurück zum Zitat Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133(10):1568–1576. doi:10.1043/1543-2165-133.10.1568 PubMed Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133(10):1568–1576. doi:10.​1043/​1543-2165-133.​10.​1568 PubMed
18.
Zurück zum Zitat Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H (1994) Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152(4):1297–1301PubMed Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H (1994) Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152(4):1297–1301PubMed
19.
Zurück zum Zitat Mazumdar M, Glassman JR (2000) Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19(1):113–132CrossRefPubMed Mazumdar M, Glassman JR (2000) Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19(1):113–132CrossRefPubMed
21.
Zurück zum Zitat Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54(8):774–781CrossRefPubMed Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54(8):774–781CrossRefPubMed
24.
Zurück zum Zitat Pettenati C, Neuzillet Y, Radulescu C, Herve JM, Molinie V, Lebret T (2015) Positive surgical margins after radical prostatectomy: What should we care about? World J Urol. doi:10.1007/s00345-015-1580-x PubMed Pettenati C, Neuzillet Y, Radulescu C, Herve JM, Molinie V, Lebret T (2015) Positive surgical margins after radical prostatectomy: What should we care about? World J Urol. doi:10.​1007/​s00345-015-1580-x PubMed
25.
Zurück zum Zitat Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA J Am Med Assoc 296(19):2329–2335. doi:10.1001/jama.296.19.2329 CrossRef Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA J Am Med Assoc 296(19):2329–2335. doi:10.​1001/​jama.​296.​19.​2329 CrossRef
26.
Zurück zum Zitat Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schroder FH, Collette L (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol: Off J Am Soc Clin Oncol 25(27):4178–4186. doi:10.1200/JCO.2006.10.4067 CrossRef Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schroder FH, Collette L (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol: Off J Am Soc Clin Oncol 25(27):4178–4186. doi:10.​1200/​JCO.​2006.​10.​4067 CrossRef
27.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137. doi:10.1016/j.eururo.2013.09.046 CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137. doi:10.​1016/​j.​eururo.​2013.​09.​046 CrossRefPubMed
28.
30.
Zurück zum Zitat Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA, J Am Med Assoc 281(15):1395–1400CrossRef Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA, J Am Med Assoc 281(15):1395–1400CrossRef
31.
Zurück zum Zitat Nguyen CT, Kattan MW (2009) Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. Cancer 115(13 Suppl):3039–3045. doi:10.1002/cncr.24355 CrossRefPubMed Nguyen CT, Kattan MW (2009) Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. Cancer 115(13 Suppl):3039–3045. doi:10.​1002/​cncr.​24355 CrossRefPubMed
Metadaten
Titel
Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins
verfasst von
Christian P. Meyer
Jens Hansen
Katharina Boehm
Derya Tilki
Firas Abdollah
Quoc-Dien Trinh
Margit Fisch
Guido Sauter
Markus Graefen
Hartwig Huland
Felix K. H. Chun
Sascha A. Ahyai
Publikationsdatum
03.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1861-z

Weitere Artikel der Ausgabe 2/2017

World Journal of Urology 2/2017 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.